Table 4.
miRNAs | mRNA targets | Cancer association | OC association |
---|---|---|---|
miR-134↓ |
|
x |
|
miR-141-3p↑ |
TGFB2↓, ZEB2↓, JAG1, BAP1, CLOCK, ELMO2, ERBB2IP, KLHL20, MAP2K4, PLCG1, PTPRD, WDR37 |
x |
x (EC) |
miR-182-5p↑ |
FOXO3, ADCY6, CASP2↑, CLDN17, NCAM1↓, NFASC↓, RARG, BCL2L14↑, CARD11↑, CASP10↑, CASP12, CDH1↑, CDH4, CDK6, CLDN15↓, COL11A2, COL4A4↓, FNDC3A↓, FOXO1↓, GADD45G↓, GJA3, IGF1R↓, INHBC, ITGA4, LRP6, MALAT1↓, MITF↓, MTSS1, NLGN2, PGF, PIK3CA↑, RPS6KB1, SOS1, VWF↑ |
x |
x (EC) |
miR-200a-3p↑ |
CTNNB1, VIM↓, ZEB1↓, ZEB2↓, BAP1, CDK6, CDKN1B↓, CTBP2, CYP1B1↑, ELMO2, ERBB2IP, KLHL20, PLCG1, PTPRD↓, TUBB↑, WDR37, ZFPM2↓ |
x |
x (EC, ROC) |
miR-200a-5p↑ |
|
x |
|
miR-200b-3p↑ |
VIM↓, ZEB1↓, ZEB2↓, BAP1, ELMO2, ERBB2IP, ERRFI1, KLHL20, PLCG1, PTPRD↓, RERE, WASF3, WDR37, ZFPM2↓ |
x |
x (ROC) |
miR-200c-3p↑ |
CDH1↑, PTPN13↓, ZEB1↓, ZEB2↓, FHOD1, PPM1F, JAG1, MARCKS, VIM↓, CDKN1B↓, ERRFI1↓, PLCG1 |
x |
x (EC) |
miR-202-3p↓ |
|
|
|
miR-205-5p↑ |
ERBB3↑, F Actin, INPPL1↑, MED1, VEGFA↑, ZEB1↓, ZEB2↓, PRKCE |
x |
x (EC) |
miR-383↓ |
|
|
|
miR-424-5p↓ |
FGFR1, MAP2K1, NFIA↓, PLAG1 |
x |
|
miR-508-5p |
|
|
|
miR-509-3p↓ |
NTRK3 |
|
|
miR-509-5p↓ |
|
|
|
miR-509-3-5p↓ |
|
|
|
miR-510↓ |
HTR3E, SPDEF↑ |
x |
|
miR-513a-5p |
CD274 |
x |
|
miR-514b-5p↓ |
IPA: Ingenuity Pathway Analysis. HGSC: High-grade serous ovarian carcinoma. OC: Ovarian carcinoma. EC: Endometrioid OC. ROC: Recurrent OC. Over- and underexpressed miRNAs (based on Tables 2 and 3) and mRNAs (based on global gene expression analysis [29]) in HGSC vs. ovarian surface epithelium (OSE) are indicated by upward and downward arrows, respectively. A complete list of HGSC vs. OSE FC values for the mRNA targets is available in Additional file 2.